IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingGlobeNewsWire • Wednesday
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewsWire • 04/16/24
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024GlobeNewsWire • 04/09/24
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/14/24
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024GlobeNewsWire • 03/05/24
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyGlobeNewsWire • 02/14/24
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline GoalsGlobeNewsWire • 01/04/24
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in LeukemiaGlobeNewsWire • 12/11/23
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private PlacementGlobeNewsWire • 12/11/23
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with LeukemiaGlobeNewsWire • 12/05/23
Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom FisherZacks Investment Research • 11/23/23
IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaGlobeNewsWire • 11/20/23
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual MeetingGlobeNewsWire • 11/10/23
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingGlobeNewsWire • 11/06/23
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingGlobeNewsWire • 11/03/23
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/02/23
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed GlioblastomaGlobeNewsWire • 10/12/23
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual MeetingGlobeNewsWire • 09/29/23
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York CityGlobeNewsWire • 09/26/23
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global PatentsGlobeNewsWire • 09/19/23